[1]张明敏,王国平.2021版国家医保药品目录限定支付情况研究[J].卫生经济研究,2023,40(3):72-75.
　ZHANG Mingmin,WANG Guoping.Study on the Limited Payment of Medical Insurance Drug List 2021[J].Journal Press of Health Economics Research,2023,40(3):72-75.
点击复制

2021版国家医保药品目录限定支付情况研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
40
期数:
2023年3期
页码:
72-75
栏目:
医疗保障
出版日期:
2023-03-01

文章信息/Info

Title:
Study on the Limited Payment of Medical Insurance Drug List 2021
作者:
张明敏1; 王国平1
1.皖南医学院，安徽 芜湖 241000
Author(s):
ZHANG Mingmin;  WANG Guoping
Wannan Medical College, Wuhu Anhui 241000, China
关键词:
医保药品目录; 限定支付; 医保基金
Keywords:
medical insurance drug list;  limited payment;  medical insurance fund
分类号:
R19
文献标志码:
A
摘要:
目的：分析《2021版药品目录》限定支付情况。方法：分析限定支付药品在药品数目、中西药占比等方面的基本情况，并与《2020版药品目录》进行对比分析。结果：《2021版药品目录》限定支付药品共计861种，其中单一限定支付药品有655种，与《2020版药品目录》相比，《2021版药品目录》变化较多；但在政策执行过程中也暴露出一些问题。结论：《2021版药品目录》将更多药品纳入医保支付范畴，对限定支付的管理更为规范，在执行过程中要统筹考虑医保基金可持续发展，结合临床诊疗指南和患者实际需要，及时调整和完善限定支付相关政策。
Abstract:
Objective To analyze the limited payment of Medicine List for National Basic Medical Insurance. Methods Number of drugs and proportion of Chinese and western drugs in the limited payment of Medical Insurance Drug List 2021 were analyzed in comparison with Medical Insurance Drug List 2020. Results A total of 861 kinds of drugs were subject to limited payment in Medical Insurance Drug List 2021, which was lower than that in Medical Insurance Drug List 2020, and there were differences in the changes of various types of drugs. Conclusion Medical Insurance Drug List 2021 includes more drugs into the scope of medical insurance payment, and limits the payment of new varieties, injection types and other high-risk varieties. The management of limited payment is more standardized. However, there are some problems to be improved in the specific application, in order to further promote the rational clinical use of drugs and the efficient use of medical insurance fund.

参考文献/References:

[1] 谭清立，林岱衡.论医保统筹进程中的医保药品目录管理[J].卫生经济研究，2021，38（3）：51-56.
[2] 蔡鸿福，张惠敏，刘茂柏.注射用质子泵抑制剂超说明书用药调查分析[J].中国现代应用药学，2016（9）：1209-1211.
[3] 俞文瑾，谭佳颖，谢泽宁，等.444例口服苹果酸奈诺沙星胶囊患者不良反应发生情况[J].临床药物治疗杂志，2021（7）：21-24.
[4] 罗芬，李一意，罗霞.2020年国家医保药品目录限定支付情况及变化趋势分析与优化建议[J].中南药学，2021（7）：1479-1484.
[5] 商艳丽.联合用药和给药剂量的干预对中药注射剂安全性的影响分析[J].中外医疗，2022（8）：33-36.
[6] 张洪成，徐凯，王人颢.医保限制性药品的使用与管理策略探讨[J].江苏卫生事业管理，2021（8）：1059-1061.
[7] 徐伟，马丽，高楠.医保药品目录动态调整机制研究[J].卫生经济研究，2017，34（11）：51-53.
[8] 中华医学会外科学分会胰腺外科学组.中国急性胰腺炎诊治指南（2021）[J].浙江实用医学，2021（6）：511-519.
[9] 杨岚钺.医保药品目录及审核规则对城乡居民医药负担的影响[D].昆明：昆明理工大学，2021.

相似文献/References:

[1]徐 伟,马 丽,高 楠.医保药品目录动态调整机制研究[J].卫生经济研究,2017,(11):51.
[2]李赛赛,徐 伟,王煜昊,等.创新药物医保目录准入研究[J].卫生经济研究,2019,(10):40.
　LI Sai-sai,XU Wei,WANG Yu-hao,et al.Research on Access to the List of Innovative Medicines[J].Journal Press of Health Economics Research,2019,(3):40.
[3]谭清立,林岱衡.论医保统筹进程中的医保药品目录管理[J].卫生经济研究,2021,38(3):50.
　TAN Qing-li,LIN Dai-heng.Discussion on the Management of Medical Insurance Drug Catalogue in the Process of Social Pooling for Medical Insurance[J].Journal Press of Health Economics Research,2021,38(3):50.
[4]郑王彪,郑 超,孙 强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62.
　ZHENG Wangbiao,ZHENG Chao,SUN Qiang.International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog[J].Journal Press of Health Economics Research,2023,40(3):62.

更新日期/Last Update: 2023-03-01